NCT03248024已完成不适用
Etude Des Facteurs Explicatifs Des Coûts de la Prise En Charge Des Patients Adultes Atteints d'Une MICI Suivis au CHRU de Nancy et traités Par biothérapie
Central Hospital, Nancy, France0 个研究点目标入组 119 人开始时间: 2016年11月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 119
- 主要终点
- Retrospective health care consumption
研究概览
简要总结
The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or adalimumab), including biosimilars (infliximab biosimilars: Inflectra ™ and Remsima ™) for treating Crohn's desease or ulcerative colitis
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients consulted at the Gastroenterology services of Nancy University Hospital during the period of inclusion
- •Patients over 18 of age the day of consultation
- •Patients treated at least one time by biotherapy during the last 12 months preceeding inclusion
- •Patients with crohn's disease or ulcerative colitis.
- •Patients accepting to respond to the questionnary
排除标准
- •Age under 18 years , the day of consultation
- •Patient that not accept or unable to complete the retrospective questionnary
结局指标
主要结局
Retrospective health care consumption
时间窗: one year
Desease treatment cost individual level data
次要结局
未报告次要终点
研究者
相似试验
尚未招募
不适用
Direct Medical Costs Associated With Negative Diagnosis of IBS.Irritable Bowel SyndromeNCT05144594Region Örebro County3,000
已完成
不适用
A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + VilanterolPulmonary Disease, Chronic ObstructiveNCT05127304Boehringer Ingelheim11,316
已完成
不适用
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional DatabaseDiabetesNCT04903496Boehringer Ingelheim1,233,162
已完成
不适用
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in FranceGastroesophageal Reflux DiseaseNCT00842855AstraZeneca275
已完成
不适用
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the USGastroesophageal Reflux Disease (GERD)NCT00795093AstraZeneca552